Medicenna Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Medicenna Therapeutics de 44.8% y 61.3% respectivamente, mientras que el BPA crecerá en un 42.9% al año.

Información clave

42.0%

Tasa de crecimiento de los beneficios

40.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	37.3%
Tasa de crecimiento de los ingresos	59.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	22 Feb 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Oct 18

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Jun 14

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Feb 28

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Nov 08

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

Mar 01

Previsiones de crecimiento de beneficios e ingresos

TSX:MDNA - Estimaciones futuras de los analistas y datos financieros pasados (CAD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	15	-9	N/A	-15	1
3/31/2026	2	-19	N/A	56	3
3/31/2025	0	-19	N/A	16	4
3/31/2024	N/A	-16	N/A	-16	4
12/31/2023	N/A	-15	-14	-14	N/A
9/30/2023	N/A	-12	-13	-13	N/A
6/30/2023	N/A	-9	-14	-14	N/A
3/31/2023	N/A	-10	-13	-13	N/A
12/31/2022	N/A	-9	-13	-13	N/A
9/30/2022	N/A	-13	-16	-16	N/A
6/30/2022	N/A	-20	-21	-21	N/A
3/31/2022	N/A	-23	-24	-24	N/A
12/31/2021	N/A	-25	-23	-23	N/A
9/30/2021	N/A	-26	-20	-20	N/A
6/30/2021	N/A	-21	-17	-17	N/A
3/31/2021	N/A	-17	-15	-15	N/A
12/31/2020	N/A	-14	-16	-16	N/A
9/30/2020	N/A	-11	-14	-14	N/A
6/30/2020	N/A	-9	-5	-5	N/A
3/31/2020	N/A	-8	-5	-5	N/A
12/31/2019	N/A	-7	-5	-5	N/A
9/30/2019	N/A	-6	-5	-5	N/A
6/30/2019	N/A	-5	-8	-8	N/A
3/31/2019	N/A	-5	-8	-8	N/A
12/31/2018	N/A	-5	-9	-9	N/A
9/30/2018	N/A	-5	-10	-10	N/A
6/30/2018	N/A	-6	-11	-11	N/A
3/31/2018	N/A	-7	-10	-10	N/A
12/31/2017	N/A	-11	-10	-10	N/A
9/30/2017	N/A	-11	N/A	-8	N/A
6/30/2017	N/A	-10	N/A	-8	N/A
3/31/2017	N/A	-8	N/A	-7	N/A
12/31/2016	N/A	-3	N/A	-6	N/A
9/30/2016	N/A	-2	N/A	-5	N/A
6/30/2016	N/A	-1	N/A	-4	N/A
3/31/2016	N/A	-1	N/A	-3	N/A
3/31/2015	N/A	-1	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que MDNA siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que MDNA siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que MDNA siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (61.3% al año) de MDNA crezcan más rápidamente que los del mercado Canadian (6.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (61.3% al año) de MDNA crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MDNA se prevé que sea elevada dentro de 3 años.

Medicenna Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased to CA$7.00

Price target increased to CA$12.00

No longer forecast to breakeven

Price target decreased to CA$10.63

Forecast to breakeven in 2025

Consensus revenue estimates fall to CA$125.0k

Recent updates

Medicenna Therapeutics Files Form 15

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors

Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab

Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp

Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting

Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer

New major risk - Revenue and earnings growth

Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer

Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer

Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023

New minor risk - Share price stability

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023

Price target decreased to CA$7.00

High number of new and inexperienced directors

Medicenna Therapeutics Corp. Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 Ability Study of Mdna11 At the Sitc Annual Meeting

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Price target increased to CA$12.00

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Lead Independent Director recently bought CA$74k worth of stock

Medicenna Therapeutics Corp. Confirms Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 Ability Study

Medicenna Therapeutics Corp. Presents Preclinical Data Demonstrating Anti-Tumor Activity of Its Anti-Pd1-Il-2 Biskit and Long-Acting Il-4/Il-13 Super-Antagonist At Cytokines 2022

Medicenna Therapeutics Corp. Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. to Report Q1, 2023 Results on Aug 15, 2022

Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp., Annual General Meeting, Sep 21, 2022

No longer forecast to breakeven

Price target decreased to CA$10.63

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11's Favorable Clinical Profile At the 2022 Frontiers in Cancer Immunotherapy Meeting

Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 Ability Study

High number of new and inexperienced directors

Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting

Forecast to breakeven in 2025

Medicenna Therapeutics Corp. Announces Management Changes

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

High number of new and inexperienced directors

Medicenna Therapeutics Corp. to Report Q3, 2022 Results on Feb 09, 2022

Medicenna Therapeutics Corp. Announces Board Appointments

Medicenna Announces Peer-Reviewed Publication of Preclinical Data on MDNA11 in the Journal for ImmunoTherapy of Cancer

Medicenna Therapeutics Corp. Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with Mdna11 Treatment in the Phase 1/2 Ability Study

Medicenna Therapeutics Corp. Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada

Founder recently bought CA$106k worth of stock

Medicenna Therapeutics Corp. Doses First Patient in MDNA11 Phase 1/2 Ability Study

Consensus revenue estimates fall to CA$125.0k

We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely

Medicenna’s IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating Its Superiority and Ability to Reprogram the Tumor Microenvironment in Pancreatic Cancer

Medicenna Therapeutics Corp. Announces Submission of Clinical Trial Application in Australia for A Phase 1/2 Study of Mdna11

Price target increased to CA$11.50

Price target increased to CA$11.25

Medicenna Therapeutics Corp. Announces Peer-Reviewed Publication of Clinical Data from Phase 2B Trial Evaluating Mdna55 in Recurrent Glioblastoma